Abstract 22P
Background
To date, empirical methods using age, type of cancer and presence of family history of cancers are used clinically to identify individuals who may benefit from genetic counselling (GC) and testing, but because these guidelines use a threshold, they provide a standard recommendation regardless of whether women have a low (e.g. 4%) or high (e.g. 40%) likelihood of being BRCA carriers. We developed the Asian Genetic Risk Calculator (ARiCa), an Asian-specific personalised genetic risk assessment tool, to determine the probability of a breast cancer patient carrying a germline BRCA1/2 pathogenic or likely pathogenic variant. The ARiCa Study was established to evaluate the impact of personalised risk score on risk perception and cancer-related distress, and uptake of GC among breast cancer patients.
Methods
The ARiCa Study is a prospective observational multicentre two-arm study where 256 incident and prevalent breast cancer patients in breast surgical clinics who have previously not received GC will be randomised to receive genetic risk assessment based on current clinical criteria (controls) or ARiCa personalised risk score. The patients’ risk perception, distress level and GC uptake were determined via researcher-administered questionnaires six weeks after risk assessment.
Results
Interim analysis of 110 patients showed that compared to controls, a greater proportion of patients receiving ARiCa scores felt that the genetic risk information provided was easy to understand (92% vs 88%, p= 0.523) and influenced their decision on GC uptake (86% vs 78%, p=0.299). More participants also proceeded with GC (47% vs 39%, p=0.526) but none of the results were statistically significant. No significant distress after receiving genetic risk assessment was reported. Patients provided with personalized scores found that the visual (96%) and numerical (90%) forms of risk presentation were more helpful than the qualitative (84%) forms.
Conclusions
These interim results showed that personalized genetic risk assessment using visual and numerical forms of risk presentation is acceptable and may be a useful tool in facilitating the uptake of GC among breast cancer patients.
Clinical trial identification
NMRR ID-21-02298-7JY (IIR).
Editorial acknowledgement
Legal entity responsible for the study
Cancer Research Malaysia.
Funding
AstraZeneca.
Disclosure
C.H. Yip: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca. A.F. Abdul Aziz: Financial Interests, Personal, Invited Speaker: Roche; Non-Financial Interests, Personal, Member of Board of Directors, a non-governmental non-profit organsiations: National Cancer Society Malaysia; Non-Financial Interests, Personal, Other, Fellow: College of Surgeons, Academy of Medicine Malaysia; Non-Financial Interests, Personal, Member: Malaysian Oncological Society. W.K. Ho, B.H. Ang: Other, Institutional, Other, Pending ARiCa trademarking: Cancer Research Malaysia. S.Y. Yoon: Financial Interests, Personal, Invited Speaker, Honorarium as invited speaker: AstraZeneca. S. Teo: Financial Interests, Institutional, Research Grant, For ARiCa Study: AstraZeneca; Other, Institutional, Other, Pending ARiCa trademarking: Cancer Research Malaysia. All other authors have declared no conflicts of interest.
Resources from the same session
462P - Cognitive function of survivors with non-central nervous system cancer and its correlates: A community rehabilitation perspective
Presenter: Ann Kuo
Session: Poster Display
Resources:
Abstract
463P - The use of antipsychotic for managing delirium in patients with cancer
Presenter: Natasya Reina
Session: Poster Display
Resources:
Abstract
464P - The prevalence and correlates of frailty and pre-frailty in elderly patients with breast cancer: A cross-sectional study from China
Presenter: Min Xiao
Session: Poster Display
Resources:
Abstract
465P - Oncological care needs of people with mental illness: A single institution experience in Australia
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
466P - Identification of patient satisfaction predictors among women attending oncology daycare unit using validated survey questionnaire (PSS Tool): An institutional experience in central India
Presenter: Rajesh Patidar
Session: Poster Display
Resources:
Abstract
467P - Evaluation of the effectiveness of a cluster management model based on evidence-based concepts in oncology nutrition case management
Presenter: Li He
Session: Poster Display
Resources:
Abstract
468P - The patterns of use of Traditional Chinese Medicine (TCM) in cancer patients in Hong Kong
Presenter: Olivia L T Chan
Session: Poster Display
Resources:
Abstract
469P - The need of special care for adolescent and young adult (AYA) cancer survivors: Perspective from oncologists in India
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
470TiP - Randomised controlled trial to evaluate the efficacy and safety of moisturising creams with or without palm-oil-derived vitamin E concentrate in addition to urea-based cream or urea-based cream alone in Capecitabine-associated Palmar-Plantar Erythrodysesthesia (ECaPPE)
Presenter: Pei-Jye Voon
Session: Poster Display
Resources:
Abstract
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract